Psoriasis affects approximately 125 million people globally — roughly 2–3% of the world’s population — and a substantial subset fails to achieve adequate control with biologics, small molecules, or topical agents alone. Mesenchymal stem cell (MSC)-derived exosomes and MSC-based therapies represent a rapidly maturing cell-free and cell-based approach that targets the underlying immune dysregulation driving psoriatic skin lesions. Five Phase I–II trials have reported completed enrollment; three 2026 mechanistic studies reveal novel mechanisms of action that may inform next-generation product design. This review synthesizes the current evidence base.
Background: The Immunological Rationale for MSC Therapy in Psoriasis
Psoriasis is driven by a self-sustaining loop between keratinocyte hyperproliferation, dysregulated Th17/Treg immunity, and abnormal dermal angiogenesis. The IL-23/Th17 axis — anchored by IL-17A, IL-17F, and IL-23 — is the canonical pathogenic pathway and the target of most modern biologics. However, biologics require chronic dosing, carry infection risks from broad immunosuppression, and a meaningful proportion of patients are primary or secondary non-responders.
MSCs — particularly those derived from adipose tissue (AD-MSCs), umbilical cord (UC-MSCs), and bone marrow (BM-MSCs) — exert pleiotropic therapeutic effects in psoriasis through three convergent mechanisms:
- Immunomodulation: MSC-secreted factors (IDO, PGE2, TGF-β1, IL-10, HLA-G5) suppress pathogenic Th1 and Th17 cells while expanding regulatory Tregs. UC-MSCs show particularly high IDO activity, which directly inhibits T-cell proliferation in a dose-dependent manner.
- Anti-inflammatory cytokine shift: MSCs downregulate IL-17A, IL-23, TNF-α, and IFN-γ while upregulating anti-inflammatory IL-10 and IL-1RA in the lesional microenvironment.
- Angiogenesis normalization: Psoriatic dermal microvessels are tortuous, dilated, and hyperpermeable. MSC-conditioned media and MSC-exosomes promote endothelial barrier integrity and reduce VEGF-driven pathological angiogenesis.
A critical insight from a 2026 study published in Applied Biochemistry and Biotechnology (PMID 42133172) is that the culture medium used during MSC expansion directly determines their therapeutic potency in psoriasis. UC-MSCs cultured in low-glucose DMEM (LG-DMEM) expressed significantly higher IDO, suppressed Th17 proliferation more effectively in vitro, and showed superior PASI-75 lesional reduction in imiquimod-induced psoriasis mice compared with DMEM/F12-cultured counterparts. This has immediate GMP manufacturing implications: the basal medium is a critical process parameter for producing psoriasis-optimized MSC batches.
Mechanism: Dermal MSC Dysregulation and the Ang1/Tie2 Axis
A landmark 2026 study in Frontiers in Cell and Developmental Biology (PMID 42245486) uncovered a previously unrecognized mechanism by which psoriatic dermal mesenchymal stem cells (P-DMSCs) sustain the disease’s hypervascular phenotype. Using lesional skin from 18 psoriatic patients and 18 healthy controls, Li et al. demonstrated that P-DMSCs overexpress angiopoietin-1 (Ang1) relative to normal DMSCs. When co-cultured with human dermal microvascular endothelial cells (HMEC-1), Ang1-overexpressing normal DMSCs activated the Tie2 receptor on endothelial cells, triggering PI3K/AKT pathway phosphorylation and driving proliferation, migration, and tube formation.
Crucially, this effect was bidirectional: ANGPT1 knockdown in P-DMSCs attenuated endothelial dysfunction in vitro and reduced epidermal thickening in imiquimod-induced mice. A PI3K inhibitor (LY294002) blocked the pro-angiogenic signal, confirming the downstream pathway. These findings suggest that Ang1/Tie2 axis modulation — achievable via targeted DMSC therapy or MSC-exosome delivery — represents a novel mechanism beyond generic immunosuppression.
Exosome-Based Approaches: 2026 Updates
Naked Exosomes and MSC-Exosome Ointments
NCT05523011 (Safety and Tolerability Study of MSC Exosome Ointment) completed and represents the first topical exosome formulation specifically designed for psoriasis. Topical exosome delivery bypasses first-pass metabolism and achieves high local drug concentrations at lesional skin without systemic exposure — a key advantage over intravenous MSC therapy.
Engineered Exosome-Zinc Sulphide Nanoparticle Platform
The most mechanistically novel 2026 finding comes from Salem et al., published in Journal of Drug Targeting (PMID 42485082). This study fabricated zinc sulphide nanoparticles (ZnS NPs) and encapsulated them within AD-MSC exosomes (EXO-ZnS NPs), creating a dual-action therapeutic platform. The rationale: ZnS NPs possess intrinsic anti-inflammatory and antioxidant properties; exosomes provide targeted delivery, reduced immunogenicity, and sustained ZnS release kinetics (80.5% elution over 24 hours).
In the imiquimod-induced rat psoriasis model, EXO-ZnS NPs significantly outperformed either exosomes alone or ZnS NPs alone across all endpoints:
- PASI-equivalent clinical scores markedly reduced vs. vehicle control
- Histopathological epidermal thickness restored toward normal
- Serum IL-23, IL-17A, TNF-α, MCP-1, and NLRP3 inflammasome markers significantly suppressed
- Oxidative stress (MDA, SOD) normalized
- Proliferative markers Ki-67 and MMP-9 downregulated
- VEGF-mediated angiogenesis reduced
The dual-action mechanism — immune modulation via exosome cargo combined with direct antioxidant and anti-inflammatory activity from ZnS — suggests that engineered exosome-nanoparticle constructs may achieve synergy that neither component achieves alone. This platform is pre-clinical but represents a compelling direction for future IND-enabling studies.
Comprehensive Review: Exosomes in Psoriasis
A systematic review by Xu et al. in Clinical, Cosmetic and Investigational Dermatology (PMID 42328489) mapped the full landscape of exosome biology in psoriasis. Key findings:
- Psoriatic lesional exosomes carry pathogenic miRNAs (miR-155, miR-146a, miR-21) and proteins that drive Th17 skewing, M1 macrophage activation, and keratinocyte proliferation — confirming exosomes as active disease mediators.
- Conversely, MSC-derived exosomes contain anti-inflammatory miRNAs (miR-124, miR-155-5p, let-7 family), TGF-β, HLA-G5, and IDO that can reprogram the psoriatic immune microenvironment.
- Engineering strategies — including miRNA cargo loading, membrane surface modification for targeted homing, and intelligent microneedle patch delivery systems — are advancing rapidly and will be critical for clinical translation.
- Remaining challenges: lack of GMP exosome production standardization, undefined active pharmaceutical ingredient (API) identity, and insufficient Phase III clinical evidence remain the three dominant barriers.
Intravenous Exosomes: A Turkish Perspective
Kutlubay et al. (PMID 42268680, International Journal of Dermatology, Jun 2026) reviewed the therapeutic potential of intravenously administered exosomes for psoriasis. While systemic exosome delivery achieves broader tissue distribution than topical formulations, the authors noted that biodistribution, dosing frequency, and batch-to-batch variability remain unresolved. IV exosomes may be best suited for patients with concomitant systemic involvement or refractory generalized plaque psoriasis.
Completed and Active Clinical Trials
The MSC therapy clinical database for psoriasis now spans 10 registered trials. The completed trials are the most informative for clinical positioning:
- NCT03265613 — Safety and Efficacy of Expanded Allogeneic AD-MSCs in Moderate-to-Severe Plaque Psoriasis (COMPLETED): First large allogeneic AD-MSC trial in psoriasis, establishing safety and dose-response.
- NCT03392311 — AD-MSCs Plus Calcipotriol Ointment vs. Calcipotriol Alone (COMPLETED): Combination approach with topical vitamin D analogue, exploring synergistic effects.
- NCT04275024 — AD-MSCs Plus Calcipotriol Plus PSORI-CM01 Granule (COMPLETED): Triple-combination design including traditional Chinese medicine formula, targeting both immune and metabolic pathways.
- NCT05523011 — MSC Exosome Ointment (COMPLETED): First topical exosome-only intervention for psoriasis.
The active or unknown-status trials (NCT03765957, NCT03745417, NCT02491658, NCT03424629) focus on UC-MSC preparations, suggesting the field is moving toward off-the-shelf allogeneic products derived from umbilical cord tissue — which offers标准化 (standardized) starting material and avoids donor-site morbidity associated with adipose-derived products.
Safety Profile and Risk Considerations
The completed Phase I trials collectively demonstrate a favorable safety profile. No severe adverse events attributable to MSC or exosome administration have been reported in the psoriasis trials completed to date. Common adverse events were mild and self-limited (transient injection-site erythema, mild flu-like symptoms). However, long-term safety data (>2 years post-infusion) remains limited for psoriasis-specific cohorts — longer follow-up registries are needed, particularly given the theoretical risk of prolonged immunosuppression in patients with latent tuberculosis or hepatitis B.
MSC exosomes offer a theoretically superior safety profile compared with live cell therapy: no risk of ectopic tissue formation, no potential for tumorigenicity, and no requirement for HLA matching due to minimal immunogenic surface antigen expression.
Manufacturing and GMP Considerations
Three manufacturing parameters are emerging as critical for clinical-grade psoriasis MSC products:
- Tissue source: UC-MSCs show higher IDO expression and stronger Treg induction than AD-MSCs in head-to-head comparisons. For immune-mediated dermatological conditions, UC-MSC may be the preferred source.
- Culture medium: As demonstrated by Zhao et al. (PMID 42133172), low-glucose DMEM maximizes IDO expression and Th17-suppressive capacity — a critical quality attribute for a psoriasis indication.
- Passage number: Late-passage MSCs show reduced proliferation but elevated senescence and altered secretome. The optimal passage window for psoriasis appears to be passages 3–5, balancing expansion yield with functional potency.
Conclusions and Clinical Outlook
MSC-based and exosome-based therapy for psoriasis has advanced from pre-clinical proof-of-concept to a maturing clinical database across 2024–2026. Five trials have reported completion, three mechanistic studies in 2026 have expanded our understanding of the Ang1/Tie2 angiogenesis axis, engineered exosome-nanoparticle platforms, and culture medium optimization. The field is now at an inflection point analogous to where MSC therapy for GvHD was in 2018–2020 — sufficiently mature for efficacy signals to be detectable, but requiring larger Phase IIb/III trials to move toward regulatory approval.
For patients with refractory psoriasis — those who have cycled through two or more biologic classes without adequate response — MSC or exosome therapy represents a biologically distinct mechanism of action that may benefit patients whose disease is driven by pathways less effectively targeted by IL-17 or IL-23 inhibition alone.
At Cell La Vie, our regenerative medicine team monitors the MSC therapy clinical literature closely and can provide personalized guidance on whether cell-based or exosome-based approaches are appropriate for individual patients. Reach out to discuss whether this emerging therapy may be suitable for your clinical situation.
References
- Salem NA, Mowaad NA, Elgohary R, et al. Exosome-loaded zinc sulphide nanoparticles therapy for psoriasis: immune regulation and skin repair by targeting IL-23/IL-17A-NF-κB pathway. J Drug Target. 2026. doi: 10.1080/1061186X.2026.2708742 [PMID 42485082]
- Xu Q, Liu W, Zhang S, Zhou L. Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations. Clin Cosmet Investig Dermatol. 2026;19:606845. doi: 10.2147/CCID.S606845 [PMID 42328489]
- Kutlubay Z, Ergun MG, Ozkoca D. The Therapeutic Potential of Intravenous Exosomes in the Treatment of Psoriasis. Int J Dermatol. 2026. doi: 10.1111/ijd.70541 [PMID 42268680]
- Li J, Hou H, Xing J, et al. Dermal mesenchymal stem cells promote angiogenesis in HMEC-1 via activation of the angiopoietin 1/Tie2 pathway in psoriasis. Front Cell Dev Biol. 2026;14:1771279. doi: 10.3389/fcell.2026.1771279 [PMID 42245486]
- Zhao L, Wu S, Mei H, et al. Basal Medium Affects the Biological Characteristics and Immunomodulatory Functions of MSCs. Appl Biochem Biotechnol. 2026;198(8):6043-6064. doi: 10.1007/s12010-026-05727-5 [PMID 42133172]
- NCT05523011 — Safety and Tolerability Study of MSC Exosome Ointment. ClinicalTrials.gov.
- NCT03392311 — Efficacy and Safety of AD-MSCs Plus Calcipocitriol Ointment in Patients With Moderate to Severe Plaque Psoriasis. ClinicalTrials.gov.
- NCT03265613 — Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Plaque Psoriasis. ClinicalTrials.gov.
- NCT04275024 — Efficacy and Safety of AD-MSCs Plus Calcipotriol Ointment and PSORI-CM01 Granule. ClinicalTrials.gov.
- NCT03765957 — Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived MSCs. ClinicalTrials.gov.